At least 25,000 people in the US are starting weight-loss drug Wegovy each week, drugmaker says [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
That's more than a capacity crowd at Madison Square Garden, which holds 19,500 people It's about five times more than were able to start the medicine each week in December, the Danish pharmaceutical giant said in an earnings call Thursday. Novo Nordisk, which also makes Ozempic for type 2 diabetes, has been limiting how much of the lowest doses of Wegovy it has made available for the past year to avoid having too many new patients start the medicines amid a shortage. The drugs are designed to be started at lower doses that gradually increase over time, to limit side effects like nausea. “Based on the progress we've made in building manufacturing capacity, our plan to gradually and continuously increase shipments of the three lowest dose strengths of Wegovy is working,” the company said in a news release. Ad Feedback Both Novo Nordisk and Eli Lilly , which makes competitor drugs Mounjaro and Zepbound, have been working to combat shortages of the medicines amid unprecedented
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Temedica Expands Its Advisory Board With Former Gematik CEO Markus Leyck Dieken [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
- Roche says weight loss drug shows promising results in early trial [CNBC]CNBC
- India's Biocon posts Q4 profit fall as higher raw material costs bite [Yahoo! Finance]Yahoo! Finance
- Roche obesity therapy leads to ~19% weight loss in Phase 1 trial [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website